Hospital
Arctic Slope Native Association LTD
Arctic Slope Native Association LTD was paid $17.70M by Medicaid between Jan 2018 and Dec 2024, across 115 billing codes. Its largest line is 99211, Office or other outpatient visit for the evaluation and management of an established patient, minimal severity — 32% of everything it billed.
33Billing provider infoARCTIC SLOPE NATIVE ASSOCIATION LTD
BARROW, AK 99723
BARROW, AK 99723
33aNPI1306933643assigned 10/06/2006
33bProvider typeCritical Access Hospital
28Total paid$17.70M
24GClaims134,599
24DCodes billed115
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Alaska
Rank by total paid#5 of 8
Median peer was paid$17.70M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 23,714 | $1.75M | |
| 2019 | 15,152 | $1.67M | |
| 2020 | 15,791 | $1.39M | |
| 2021 | 21,829 | $2.92M | |
| 2022 | 21,033 | $3.61M | |
| 2023 | 20,451 | $3.54M | |
| 2024incomplete | 16,629 | $2.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 32% | 19,144 | 11,889 | $5.58M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 13% | 5,787 | 4,470 | $2.26M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 12% | 5,122 | 3,668 | $2.19M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 11% | 9,915 | 7,547 | $1.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.1% | 2,999 | 2,277 | $1.26M |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 2,059 | 1,279 | $562K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.8% | 2,347 | 1,759 | $500K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.7% | 10,734 | 7,987 | $478K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 1.6% | 431 | 369 | $281K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 913 | 741 | $226K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 1,584 | 1,172 | $220K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.0% | 1,577 | 1,401 | $183K |
103 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,344 | $176K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 218 | $151K |
| 92015 | Determination of refractive state | <1% | 1,649 | $134K |
| 71045 | Radiologic examination, chest; single view | <1% | 502 | $129K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 73 | $121K |
| 99284 | Emergency room visit (serious) | <1% | 309 | $116K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,130 | $109K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 28 | $95K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 255 | $92K |
| 80053 | Comprehensive metabolic panel | <1% | 7,606 | $68K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,218 | $65K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,214 | $65K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 498 | $60K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,949 | $59K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,732 | $52K |
| 93976 | <1% | 64 | $42K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,662 | $41K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,334 | $34K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,635 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 82 | $31K |
| 99285 | Emergency room visit (most serious) | <1% | 30 | $28K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 127 | $25K |
| 0240U | <1% | 199 | $24K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,488 | $24K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,352 | $23K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 48 | $20K |
| 84703 | <1% | 2,785 | $17K | |
| 94760 | <1% | 136 | $17K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,963 | $16K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 64 | $14K |
| 84439 | <1% | 1,862 | $14K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,061 | $14K |
| 80061 | Lipid panel | <1% | 1,207 | $14K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 430 | $13K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 37 | $12K |
| 81001 | <1% | 4,033 | $11K | |
| 86710 | <1% | 847 | $10K | |
| 84484 | <1% | 960 | $10K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 762 | $9K |
| 83690 | <1% | 1,542 | $9K | |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 572 | $9K |
| 83735 | <1% | 1,346 | $7K | |
| 83880 | <1% | 214 | $6K | |
| 73630 | <1% | 14 | $6K | |
| 36000 | <1% | 44 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 217 | $5K |
| 94644 | <1% | 39 | $4K | |
| J3490 | Unclassified drugs | <1% | 55 | $4K |
| M0240 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses | <1% | 18 | $4K |
| 87430 | <1% | 386 | $3K | |
| 81002 | <1% | 943 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 612 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 55 | $2K |
| 85610 | <1% | 511 | $2K | |
| 87210 | <1% | 471 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 84 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 226 | $1K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 577 | $1K |
| 87420 | <1% | 119 | $1K | |
| 0002A | <1% | 60 | $937.34 | |
| 82607 | <1% | 65 | $857.31 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,650 | $812.96 |
| 83605 | <1% | 75 | $753.84 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 23 | $652.49 |
| 86592 | <1% | 170 | $618.94 | |
| 87040 | <1% | 52 | $525.84 | |
| 84702 | <1% | 28 | $398.30 | |
| 86803 | <1% | 26 | $355.33 | |
| 87081 | <1% | 71 | $344.43 | |
| 87070 | <1% | 45 | $330.21 | |
| 86140 | <1% | 62 | $310.95 | |
| 82728 | <1% | 29 | $299.86 | |
| 82947 | <1% | 106 | $299.36 | |
| 86850 | <1% | 30 | $224.71 | |
| 85651 | <1% | 61 | $217.77 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 28 | $216.90 |
| 80179 | <1% | 13 | $205.04 | |
| 82746 | <1% | 16 | $191.10 | |
| 87340 | <1% | 12 | $123.44 | |
| 83550 | <1% | 17 | $87.40 | |
| 83540 | <1% | 18 | $71.17 | |
| 86901 | <1% | 30 | $68.77 | |
| 86900 | <1% | 30 | $68.77 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 13 | $62.10 |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14 | $34.99 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12 | $9.40 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 15 | $2.25 |
| 80320 | 0% | 1,672 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 103 | $0.00 |
| 0001A | 0% | 65 | $0.00 | |
| 80329 | 0% | 86 | $0.00 | |
| 90474 | 0% | 14 | $0.00 | |
| D0120 | Dental checkup, returning patient | 0% | 17 | $0.00 |
| D1206 | Topical application of fluoride varnish | 0% | 67 | $0.00 |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 0% | 51 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 67 | $0.00 |
| 0003A | 0% | 32 | $0.00 | |
| 96381 | 0% | 12 | $0.00 | |
| 85048 | 0% | 21 | $0.00 | |
| 85004 | 0% | 21 | $0.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 0% | 21 | $0.00 |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 0% | 16 | $0.00 |
| D1120 | Dental cleaning, child | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUCATCAT, JAIME (REVENUE CYCLE DIRECTOR)